Drug From Sea Creature Proves Promising Against Ovarian Cancer

David Kroll
, ContributorOpinions expressed by Forbes Contributors are their own.

Continued from page 1

The study design also allowed for patients whose disease progressed on topotecan to be given the choice to then receive lurbinectedin. However, it’s not clear how this factor was accounted for in the overall topotecan survival data.

Nevertheless, the continued survival of many patients receiving lurbinectedin is highly promising and bodes well continuing the path to approval in the EU and elsewhere.

PharmaMar now plans a Phase III trial in patients with platinum-resistant ovarian cancer.

Authors' potential financial conflicts of interest: Several of the authors were PharmaMar employees and received company stock while others disclosed the receipt of honoraria or consultant/advisory fees from PharmaMar and Roche.

To read more of my continued coverage of drugs derived from nature, follow me on Twitter @DavidKroll, subscribe to my posts here at Forbes.com (click the "Follow" box to the right of my photo), or "like" my science and medical writing page at Facebook.